NYMX Nymox Pharmaceutical

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.
Company profile
Ticker
NYMX
Exchange
Website
CEO
Paul Averback
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
NYMX stock data
()
News
Nymox Shares Spike To Session High Following Circulation Of European Patent Office Application For Co.'s 'NX-1207 FOR USE IN METHODS OF REDUCING THE NEED FOR SURGERY IN PATIENTS SUFFERING FROM BENIGN PROSTATIC HYPERPLASIA'
15 Mar 21
95 Biggest Movers From Yesterday
5 Feb 21
Nymox Pharma Shares Spike To Session High On Volume, Up 10.3%, Following Circulation Of World Intellectual Property Organization IP Portal Specifications For 'FOCAL TREATMENT OF PROSTATE CANCER'
4 Feb 21
Press releases
Calendar
29 Mar 21
13 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Institutional ownership Q3 2019
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
13F holders |
Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares |
Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners |
Shares | Value |
---|
Financial report summary
?Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
accuracy, Addressing, andthe, Augusta, besufficient, CFY, comfort, Conceptual, derecognition, disruption, downstream, draft, essential, exact, fashion, Fulfilling, fundamental, goodwill, interpretation, Inventory, investee, irrespective, mentioned, pandemic, parent, slowdown, TPS, travel, unconsolidated, understood, USD
Financial reports
20-F
2020 FY
Annual report (foreign)
29 Mar 21
20-F
2019 FY
Annual report (foreign)
30 Mar 20
20-F
2018 FY
Annual report (foreign)
29 Mar 19
20-F/A
2017 FY
Annual report (foreign) (amended)
11 May 18
20-F
2017 FY
Annual report (foreign)
29 Mar 18
20-F
2016 FY
Annual report (foreign)
30 Mar 17
20-F
2015 FY
Annual report (foreign)
30 Mar 16
20-F
2014 FY
Annual report (foreign)
30 Mar 15
20-F
2013 FY
Annual report (foreign)
13 Mar 14
20-F
2012 FY
Annual report (foreign)
14 Mar 13
Current reports
6-K
Notice of the Annual General Meeting of the Shareholders
20 Nov 20
6-K
Current report (foreign)
19 Nov 20
6-K
2020 Q3
Current report (foreign)
13 Nov 20
6-K
Current report (foreign)
13 Oct 20
6-K
Nymox Announces Closing of $9 Million Registered Direct Offering
14 Aug 20
6-K
Current report (foreign)
14 Aug 20
6-K
Current report (foreign)
12 Aug 20
6-K
Nymox Announces $9 Million Registered Direct Offering
12 Aug 20
6-K
Current report (foreign)
20 Jul 20
6-K
2020 Q1
Current report (foreign)
14 May 20
Registration and prospectus
424B5
Prospectus supplement for primary offering
14 Aug 20
424B5
Prospectus supplement for primary offering
13 Aug 20
424B5
Prospectus supplement for primary offering
17 Jul 20
F-3
Shelf registration (foreign)
3 Apr 20
424B5
Prospectus supplement for primary offering
8 Feb 16
F-3
Shelf registration (foreign)
13 Jul 15
424B3
Prospectus supplement
23 Mar 03
POS AM
Prospectus update (post-effective amendment)
11 Mar 03
POS AM
Prospectus update (post-effective amendment)
29 Jul 02
F-3
Shelf registration (foreign)
31 Mar 02
Proxies
No filings
Other
EFFECT
Notice of effectiveness
13 May 20
CORRESP
Correspondence with SEC
6 May 20
UPLOAD
Letter from SEC
9 Apr 20
UPLOAD
Letter from SEC
20 Nov 16
CORRESP
Correspondence with SEC
14 Nov 16
UPLOAD
Letter from SEC
31 Oct 16
UPLOAD
Letter from SEC
20 Sep 16
CORRESP
Correspondence with SEC
3 Aug 15
EFFECT
Notice of effectiveness
3 Aug 15
UPLOAD
Letter from SEC
23 Jul 15
Ownership
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
12 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
10 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
9 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
3 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
2 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
1 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
28 Jun 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
27 Jun 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
26 Jun 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
21 Jun 19
Patents
APP
Utility
Focal Treatment of Prostate Cancer
4 Feb 21
The embodiments include methods of treating prostate cancer by administering to a low grade unifocal prostate cancer tumor a composition comprising a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of a low grade unifocal prostate cancer tumor, wherein administration reduces cancer incidence, cancer grade, and cancer progression (worsening) in the entire hemi-prostate where the initial focus was located and treated.
APP
Utility
Methods of Treating Multifocal Cancer
4 Feb 21
The embodiments include methods of treating (preventing or reducing the incidence of) multifocal cancer by administering to a unifocal cancer focus a composition comprising a therapeutically effective amount of a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of the unifocal cancer tumor, wherein administration reduces multifocal cancer incidence, multifocal cancer grade, and multifocal cancer progression (worsening) in the entire organ or organism.
APP
Utility
Method of Enhancing the Therapeutic Efficacy of Fexapotide Triflutate In Treating Luts
18 Nov 20
Disclosed are methods of enhancing the therapeutic efficacy of Fexapotide Triflutate (TF) in treating LUTS, both irritative and obstructive, that include administering a composition comprising FT at least twice over a period spanning more than one year.
APP
Utility
Method of Treating Lower Urinary Tract Symptoms with Fexapotide Triflutate
18 Nov 20
Disclosed are methods of treating symptoms of Lower Urinary Tract Symptoms (LUTS), both obstructive and irritative, that include identifying patients having benign prostatic hyperplasia (BPH), and who also have LUTS, and administering a composition comprising FT to the so-identified patient.
APP
Utility
Method of Improving Lower Urinary Tract Symptoms
18 Nov 20
The embodiments include methods of improving the symptoms of mammals having LUTS, using compositions containing Fexapotide Triflutate and a pharmaceutically acceptable carrier.
Reddit threads
Daily Discussion Thread - March 29th, 2021
29 Mar 21
Daily Discussion Thread - March 26th, 2021
26 Mar 21
Upcoming Biotech Catalysts - 1Q 2021
5 Feb 21
Daily Discussion Thread - November 11th, 2020
11 Nov 20
Daily Discussion Thread - November 10th, 2020
10 Nov 20
Daily Discussion Thread - November 9th, 2020
9 Nov 20